Reference priceUSD $630.00Original source price: INR 52,500.00. Converted estimates are available by currency selection.
| Brand | Inqovi |
|---|---|
| Manufacturer | Taiho Oncology, Inc. |
| Prescription required | Yes |
Inqovi 35mg/100mg tablets 5 x 1 (decitabine and cedazuridine)
decitabine and cedazuridine
Description
Inqovi 35mg/100mg tablets 5 x 1 (decitabine and cedazuridine) is a medicine catalog record in the MediPriceHub database. Active ingredient: decitabine and cedazuridine. Clinical use summary: See the Benefits field on this page for the product-specific indication or intended use. That field is kept separate from catalog metadata so users can distinguish clinical information from packaging information. Manufacturer or supplier: Taiho Oncology, Inc.. Therapeutic category: Medicine Library > Oncology Medicines > Myeloma (myelofibrosis) drugs. Pack information: 35 / 100 5. Origin country or market: United States. This page is for medicine catalog reference only and should be read together with the approved prescribing information in the patient or buyer's country.Benefits
INQOVI is a combination of decitabine, a nucleoside metabolic inhibitor, and cedazuridine, a cytidine deaminase inhibitor, indicated: For treatment of adult patients with myelodysplastic syndromes (MDS), including previously treated and untreated, de novo and secondary MDS with the following French-American-British subtypes (refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, and chronic myelomonocytic leukemia [CMML]) and intermediate-1, intermediate-2, and high-risk International Prognostic Scoring System groups. In combination with venetoclax for the treatment of newly diagnosed acute myeloid leukemia (AML) in adults 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy.How to Use
Use decitabine and cedazuridine under the supervision of a qualified healthcare professional. Take it by mouth only according to the approved label and the dose prescribed by a qualified healthcare professional. Do not start, stop, change the dose, split or crush a dosage form, mix with other medicines, or repeat a course unless the approved product information or a clinician confirms that it is appropriate. Check the local prescribing information for age limits, dose adjustments, missed-dose instructions, storage after opening or reconstitution, and monitoring requirements.Specification
Active ingredient: decitabine and cedazuridine. Pack size: 35 / 100 5. Pack unit: box. Manufacturer: Taiho Oncology, Inc.. Origin country: United States. Source category: Medicine Library > Oncology Medicines > Myeloma (myelofibrosis) drugs. Availability, prescription status, storage, and exact approved use may vary by country. Check the local product information before clinical or procurement decisions.Side Effects
Cancer medicines may cause fatigue, nausea, vomiting, diarrhea or constipation, appetite changes, mouth sores, rash, changes in blood counts, infection risk, liver or kidney test changes, bleeding risk, neuropathy, infusion reactions, or organ-specific toxicity depending on the medicine. Seek urgent medical care for severe allergic symptoms, breathing difficulty, fainting, severe skin reactions, chest pain, confusion, serious bleeding, signs of infection, or rapidly worsening symptoms. The approved local prescribing information is the controlling source for the complete adverse-reaction profile.This information is for reference only. Consult a qualified healthcare professional before using any medicine.